Once-Weekly GZR4 Beats Insulin Glargine in SUPER-1 Phase 3 Trial
Start here
At EASD 2026, Professor Chen Liming presented results from SUPER-1, a multicenter, randomized, open-label phase 3a trial in 589 insulin-naive patients with type 2 diabetes. Once-weekly GZR4 delivered a greater 26-week HbA1c reduction than once-daily insulin glargine U100: HbA1c fell 1.45% versus 1.22% from baseline, with an estimated treatment difference of -0.23% (95% CI -0.34 to -0.12, P < 0.0001). The findings position GZR4 as a weekly basal-insulin alternative that outperformed a daily standard on glycemic control in this insulin-naive population. Open questions include full safety and hypoglycemia details, regulatory filing plans, and whether the benefit holds in broader or longer-term use.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickProfessor Chen Liming Explains GZR4 SUPER-1 Phase 3 Superior HbA1c Results at EASD 2026
Results of the SUPER-1 phase 3 trial, presented by Professor Chen Liming at EASD 2026, show that once-weekly GZR4 achieved a greater 26-week HbA1c reduction than once-daily insulin glargine U100. The multicenter, randomized, open-label phase 3a study enrolled 589 insulin-naive patients with type 2 diabetes; HbA1c fell 1.45% versus 1.22% from baseline, with an ETD of -0.23% (95% CI -0.34 to -0.12, P < 0.0001).
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 23 18:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.